<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122834">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080572</url>
  </required_header>
  <id_info>
    <org_study_id>AG033947-03A1</org_study_id>
    <secondary_id>2R44AG033947-03A1</secondary_id>
    <nct_id>NCT02080572</nct_id>
  </id_info>
  <brief_title>Parkinstep: Automated PD Gait and Balance Assessment for Optimizing DBS</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Lakes NeuroTechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Case Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Great Lakes NeuroTechnologies Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Changes in deep brain stimulation (DBS) settings can have a delayed effect on gait function,
      which makes it impractical to optimize DBS for gait parameters in the clinic. Wearable
      movement sensors could be used to assess gait impairment in the patient's home hours after
      treatment adjustments are made in the clinic. This study aims to quantitatively evaluate the
      effects of turning off deep brain stimulation on lower extremity and gait function over
      three hours. This study will provide vital information about our patient worn system's
      ability to detect changes in lower impairment over time, which could be used to assist with
      DBS tuning for the lower extremities and gait in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Effect of DBS cessation on motor function over time</measure>
    <time_frame>All data will be collected within a single session not to exceed 4 hours. All data will be analyzed within one month of study completion.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor function evaluations (movement speed and magnitude) will be collected at various time points after DBS cessation. The effects over time will be examined.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease With Deep Brain Stimulation</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease with DBS</arm_group_label>
    <description>Individuals with Parkinson's disease and deep brain stimulation will be recruited.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Parkinson's disease, gait impairment, and deep brain stimulation will be
        recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's disease

          -  Age &gt; 21

          -  Underwent DBS surgery targeting the subthalamic nucleus (STN)

          -  Bilateral or midline involvement when &quot;off&quot; DBS/medication state

          -  Clinical history of gait impairment or freezing of gait

        Exclusion Criteria:

          -  &quot;Parkinson's plus&quot; syndrome, secondary, or atypical Parkinson's disease

          -  Underwent DBS surgery targeting the ventral intermediate (VIM)

          -  Unable to walk independent of a wheelchair (use of assistive devices, like a cane, is
             okay for this study)

          -  Dementia (determined by a neuropsychological assessment).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph P Giuffrida, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Lakes NeuroTechnologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Brokaw, PhD</last_name>
    <phone>216-446-2453</phone>
    <email>ebrokaw@glneurotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Labor</last_name>
      <email>laberca2@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Alberto Espay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredy Revilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parianne Fatica</last_name>
      <email>Parianne.Fatica@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>David Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
